Naturally Occurring PCSK9 Inhibitors

Genetic, epidemiological and pharmacological data have led to the conclusion that antagonizing or inhibiting Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces cardiovascular events. This clinical outcome is mainly related to the pivotal role of PCSK9 in controlling low-density lipoprotei...

Descripción completa

Detalles Bibliográficos
Autores principales: Adorni, Maria Pia, Zimetti, Francesca, Lupo, Maria Giovanna, Ruscica, Massimiliano, Ferri, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284437/
https://www.ncbi.nlm.nih.gov/pubmed/32429343
http://dx.doi.org/10.3390/nu12051440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284437/
https://www.ncbi.nlm.nih.gov/pubmed/32429343
http://dx.doi.org/10.3390/nu12051440

Ejemplares similares